FDA Approves Breyanzi for Relapsed, Refractory Marginal Zone Lymphoma

MONDAY, Dec. 15, 2025-- The U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatment or relapsed after two or more prior...